Joshi highlights pivotal role of academia–industry collaboration
In line with the growing emphasis on strengthening industry–academia partnerships to drive innovation and translational research in India’s pharmaceutical sector, the National Institute of Pharmaceutical Education and Research (NIPER) Hajipur has signed a Memorandum of Understanding (MoU) with Boehringer Ingelheim India Pvt Ltd, marking a significant step towards fostering collaborative research and accelerating healthcare solutions.
Under this partnership, German-origin Boehringer Ingelheim will provide researchers access to its opnMe® open science platform, enabling wider scientific exchange and accelerating healthcare innovation. The collaboration will build research capacity at NIPER Hajipur, provide students with hands-on training, and generate early-stage proof-of-concept data that can be scaled into preclinical development. By harnessing a resource-efficient, integrated research framework, the partnership aims to translate scientific discoveries into viable therapies, positioning NIPER Hajipur as a leader in translational pharmacology.
The MoU was signed in the presence of Manoj Joshi, Secretary, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers at Kartavya Bhawan in New Delhi.
Speaking on the occasion on 24 April, Manoj Joshi highlighted the pivotal role of academia–industry collaboration in bridging the gap between research and commercialisation and fostering innovation.
The collaboration between NIPER Hajipur and Boehringer Ingelheim is expected to foster synergy between academia and industry and contribute to the development of next-generation therapies and support the broader objective of building a robust, innovation-driven healthcare ecosystem in the country. Fiinews.com
